- Home
- NEWP vs CMPX Comparison
NEWP vs CMPX Comparison
Compare NEWP & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- CMPX
- Stock Information
- Founded
- NEWP 1972
- CMPX 2014
- Country
- NEWP Canada
- CMPX United States
- Employees
- NEWP N/A
- CMPX N/A
- Industry
- NEWP
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- CMPX Health Care
- Exchange
- NEWP Nasdaq
- CMPX Nasdaq
- Market Cap
- NEWP 199.1M
- CMPX 229.5M
- IPO Year
- NEWP N/A
- CMPX N/A
- Fundamental
- Price
- NEWP $1.17
- CMPX $1.82
- Analyst Decision
- NEWP Strong Buy
- CMPX Strong Buy
- Analyst Count
- NEWP 1
- CMPX 8
- Target Price
- NEWP $5.00
- CMPX $13.13
- AVG Volume (30 Days)
- NEWP 206.5K
- CMPX 762.7K
- Earning Date
- NEWP 05-07-2025
- CMPX 05-08-2025
- Dividend Yield
- NEWP N/A
- CMPX N/A
- EPS Growth
- NEWP N/A
- CMPX N/A
- EPS
- NEWP N/A
- CMPX N/A
- Revenue
- NEWP N/A
- CMPX $850,000.00
- Revenue This Year
- NEWP N/A
- CMPX $47.65
- Revenue Next Year
- NEWP N/A
- CMPX $2,622.79
- P/E Ratio
- NEWP N/A
- CMPX N/A
- Revenue Growth
- NEWP N/A
- CMPX N/A
- 52 Week Low
- NEWP $0.93
- CMPX $0.77
- 52 Week High
- NEWP $2.53
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- NEWP 51.25
- CMPX 46.49
- Support Level
- NEWP $1.13
- CMPX $1.79
- Resistance Level
- NEWP $1.20
- CMPX $1.95
- Average True Range (ATR)
- NEWP 0.06
- CMPX 0.14
- MACD
- NEWP -0.00
- CMPX 0.01
- Stochastic Oscillator
- NEWP 53.33
- CMPX 29.52
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.